EUVIMEDEUVIMED entdecken
Open Access

ALKBH5 orchestrates ferroptosis-driven tumor suppression: An LLM-powered discovery in prostate cancer

Xianyanling Yi, Zeyu Han, Dazhi Lu, Hang Xu, Xiaonan Zheng, Yaxiong Tang, Jin Li, Xuanji Li, Dazhou Liao, Hong Li, Qiang Wei, Lu Yang und 2 weitere

Molecular Therapy · 2026

DOI: 10.1016/j.ymthe.2026.02.003 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecular Therapy, 2026. Verfasst von Xianyanling Yi und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Institute of Urology, West China Hospital, Sichuan University, No. 37 Guoxue Lane, Chengdu 610041, China. Hauptthemen laut MEDLINE: Ferroptosis, Prostatic Neoplasms, AlkB Homolog 5, RNA Demethylase. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 63 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Science and Technology Department of Sichuan Province, West China Hospital of Sichuan University, Key Technologies Research and Development Program.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The treatment of prostate cancer (PCa) continues to pose substantial clinical challenges. The use of large language models (LLMs) to identify the key molecular determinants of PCa progression, followed by experimental biological validation, helps uncover novel therapeutic targets. We developed hierarchical knowledge-guided LLM for risk gene identification (HKLLM-RG), a PCa risk gene identification method. Among the candidate genes identified, ALKBH5 emerged as particularly noteworthy in the analysis. Reduced expression of ALKBH5 correlated with aggressive clinical features and significantly reduced survival in PCa. ALKBH5 inhibits PCa progression and promotes ferroptosis. CHRM3, which is the downstream molecule of ALKBH5, could promote PCa cell proliferation and migration. ALKBH5 regulates CHRM3 in an m6A-dependent manner. Mechanistically, the ALKBH5/CHRM3 axis suppresses AKT signaling, thereby inducing the upregulation of the transcriptional repressor ZNF281. This regulatory cascade subsequently downregulates the expression of SLC3A2 and GPX4, ultimately sensitizing cells to ferroptosis. Thus, AZD5363 and RSL3 targeting the ALKBH5/CHRM3/ZNF281 axis can effectively synergize to treat PCa by promoting ferroptosis. Taken together, this study leverages LLM-guided discovery to delineate a novel ALKBH5/CHRM3/ZNF281 regulatory axis controlling ferroptotic susceptibility in PCa. Importantly, a synergistic therapeutic strategy was identified by combining RSL3 with AZD5363, providing novel therapeutic targets and directions for PCa treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

FerroptosisProstatic NeoplasmsAlkB Homolog 5, RNA DemethylaseMaleHumansAnimalsGene Expression Regulation, NeoplasticLarge Language ModelsCell Line, TumorMiceSignal TransductionCell Proliferation

Stichwörter der Autor:innen

ALKBH5artificial intelligenceferroptosislarge language modelsprostate cancer

Substanzen

AlkB Homolog 5, RNA DemethylaseALKBH5 protein, human

Autor:innen und Institutionen

  • Department of Urology, Institute of Urology, West China Hospital, Sichuan University, No. 37 Guoxue Lane, Chengdu 610041, China.
  • AI for Science Interdisciplinary Research Center, School of Computer Science, Northwestern Polytechnical University, No. 1 Dongxiang Road, Xi'an 710129, China.
  • Department of Urology, Institute of Urology, West China Hospital, Sichuan University, No. 37 Guoxue Lane, Chengdu 610041, China; Department of Urology, Sichuan Provincial People's Hospital, University of Electronic Scie…
  • Department of Urology, Institute of Urology, West China Hospital, Sichuan University, No. 37 Guoxue Lane, Chengdu 610041, China. Electronic address: wycleflue@scu.edu.cn.
  • AI for Science Interdisciplinary Research Center, School of Computer Science, Northwestern Polytechnical University, No. 1 Dongxiang Road, Xi'an 710129, China. Electronic address: jiajiepeng@nwpu.edu.cn.
  • Department of Urology, Institute of Urology, West China Hospital, Sichuan University, No. 37 Guoxue Lane, Chengdu 610041, China. Electronic address: jianzhong.ai@wchscu.edu.cn.

Förderung

  • Science and Technology Department of Sichuan Province
  • West China Hospital of Sichuan University
  • Key Technologies Research and Development Program
  • National Key Research and Development Program of China
  • Sichuan University
  • National Natural Science Foundation of China

Zitieren

APA

Yi, X., Han, Z., Lu, D., Xu, H., Zheng, X., Tang, Y., Li, J., Li, X., Liao, D., Li, H., Wei, Q., Yang, L., Peng, J., & Ai, J. (2026). ALKBH5 orchestrates ferroptosis-driven tumor suppression: An LLM-powered discovery in prostate cancer. Molecular Therapy. https://doi.org/10.1016/j.ymthe.2026.02.003

Vancouver

Yi X, Han Z, Lu D, Xu H, Zheng X, Tang Y, et al. ALKBH5 orchestrates ferroptosis-driven tumor suppression: An LLM-powered discovery in prostate cancer. Molecular Therapy. 2026. doi:10.1016/j.ymthe.2026.02.003

BibTeX
@article{Yi2026,
  author = {Yi, Xianyanling and Han, Zeyu and Lu, Dazhi and Xu, Hang and Zheng, Xiaonan and Tang, Yaxiong and Li, Jin and Li, Xuanji and Liao, Dazhou and Li, Hong and Wei, Qiang and Yang, Lu and Peng, Jiajie and Ai, Jianzhong},
  title = {ALKBH5 orchestrates ferroptosis-driven tumor suppression: An LLM-powered discovery in prostate cancer},
  journal = {Molecular Therapy},
  year = {2026},
  doi = {10.1016/j.ymthe.2026.02.003}
}
Kostenlos starten →